GRAL Stock: GRAIL Inc. Business Overview

2026 Update: GRAL Price, Galleri Results, and FDA Review

This GRAL stock overview was updated on October 27, 2026. Market data are through October 26, the latest completed U.S. trading session. Financial and operating data are through GRAIL's second quarter ended June 30, 2026.

GRAL closed at $139.91, with a $41.50–$166.48 52-week range and a market capitalization of approximately $6.249 billion. The company remained unprofitable, with trailing EPS of -$9.70 and no meaningful P/E ratio.

In Q2 2026, GRAIL generated $44.7 million in total revenue, up 26% year over year. Galleri revenue was $42.6 million, and quarterly test volume exceeded 61,000. The company reported a $110.2 million net loss and held $861.6 million in cash, cash equivalents, and short-term marketable securities at quarter-end.

The regulatory picture also changed materially. On September 23, 2026, an FDA advisory committee voted favorably on Galleri's safety, effectiveness, and benefit-risk profile for adults aged 50 and older. The committee's recommendation was not final FDA approval, and the agency's decision remained pending at the editorial cutoff.

Eligible users can review available market and product information on the Bybit TradFi GRAL page. Availability and terms vary by jurisdiction.

The original overview contained outdated leadership, headquarters, clinical-trial, and financial information. The durable explanation of Galleri's science remains below, updated to reflect the latest evidence and regulatory status.

GRAL Stock: Key Facts at a Glance

Market and corporate facts can change. The table is a dated snapshot, not a live quote.

What Is GRAL Stock?

GRAL is the Nasdaq ticker symbol for GRAIL, Inc., a healthcare company focused on blood-based cancer screening and precision oncology. The ticker is not a separate product or acronym for GRAIL's technology.

GRAIL's principal commercial product is Galleri, a multi-cancer early detection test. Galleri looks for cancer-associated methylation patterns in cell-free DNA from a blood sample and, when it detects a signal, predicts the likely cancer signal origin.

The test is designed for people without symptoms who have an elevated cancer risk, such as adults aged 50 or older. It is intended to be used alongside recommended screening, not as a replacement for mammography, colonoscopy, cervical screening, lung screening, or other guideline-based care.

Galleri is a screening test, not a diagnosis. A cancer-signal-detected result requires clinical evaluation, and a no-cancer-signal result does not rule out cancer.

GRAIL's History and Illumina Separation

GRAIL was founded in 2015 with backing from Illumina, a genomic-sequencing company. It later operated independently before Illumina announced an approximately $8 billion acquisition in 2020 and completed it in 2021.

U.S. and European regulators challenged the transaction on competition grounds. Illumina subsequently separated GRAIL in June 2024. GRAIL common stock began regular-way trading on Nasdaq under GRAL on June 25, 2024.

This was a spin-off and regulatory divestiture rather than a traditional initial public offering. There was no conventional IPO price at which GRAIL sold shares to the public. The first regular-way trading session closed at $17.00.

Josh Ofman serves as CEO. The latest official release lists the company's headquarters in Sunnyvale, California, replacing older references to Menlo Park.

What Does GRAIL Do?

GRAIL develops and commercializes genomic tests intended to identify cancer-associated signals earlier. Its targeted methylation platform supports screening and research applications across the cancer-care continuum.

Galleri currently generates most of the company's commercial revenue. GRAIL also provides development services and researches applications such as risk stratification, minimal residual disease, recurrence monitoring, and other precision-oncology uses. Development programs should not be treated as approved or commercial products unless current company and regulatory disclosures support that status.

GRAIL makes money primarily through paid Galleri testing. Access can include physician-ordered, employer, health-system, and selected health-plan channels. Broad insurance reimbursement has not yet made the test a routine covered benefit for the full target population.

How the Galleri Test Works

Cell-free DNA and methylation

Cells release small fragments of DNA into the bloodstream. These fragments are known as cell-free DNA, or cfDNA. Cancer cells can shed cfDNA with abnormal methylation patterns—chemical marks that affect gene activity without changing the underlying DNA sequence.

Galleri uses next-generation sequencing to read selected methylation patterns and machine-learning models to classify them. The process is designed to answer two questions:

1. Is a cancer-associated signal present?
2. If so, what is the most likely cancer signal origin?

The origin prediction can help guide diagnostic evaluation, but it is not a confirmed tumor location. Physicians may use imaging, tissue biopsy, laboratory testing, or other procedures to determine whether cancer is present.

Multi-cancer early detection

Traditional screening programs generally target one cancer at a time. Multi-cancer early detection, or MCED, aims to screen for signals associated with many cancers from one sample, including cancers that do not currently have standard population-level screening.

The potential benefit is broader detection from a single blood draw. The challenge is demonstrating that population screening finds clinically important cancers early enough to improve outcomes without creating disproportionate harm from false positives, overdiagnosis, or unnecessary follow-up.

Galleri Test Accuracy and Limitations

Two common performance measures are sensitivity and specificity:

• Sensitivity measures how often a test detects a cancer signal when cancer is present.
• Specificity measures how often it reports no signal when cancer is absent.

Galleri's sensitivity varies by cancer type and stage. Later-stage cancers generally shed more detectable material, so an aggregate sensitivity percentage can hide important differences. A claim about overall sensitivity should therefore state the study population, stages, cancer types, and test version.

The PATHFINDER study reported specificity of approximately 99.1%. High specificity limits false-positive signals, but even a small false-positive rate can affect many people when a test is used across a large population.

Galleri should not replace established screening, and it cannot detect every cancer. Patients should discuss screening choices and follow-up with a qualified healthcare professional.

NHS-Galleri and PATHFINDER 2 Results

The original article described NHS-Galleri results as forthcoming. GRAIL presented detailed NHS-Galleri and PATHFINDER 2 findings in 2026.

NHS-Galleri

The NHS-Galleri trial studied repeated Galleri screening at population scale in England. GRAIL reported that adding Galleri increased cancer detection and increased the number of early-stage cancers found through screening.

The main limitation is important: the trial did not achieve a statistically significant reduction in the combined Stage III and IV endpoint. GRAIL reported a 22% reduction in Stage IV diagnoses for 12 prespecified aggressive cancers in the second screening round and a 26% reduction in the third round, along with other secondary findings.

Those results support continued analysis but should not be summarized simply as a successful or failed trial. The primary endpoint, secondary findings, study design, and clinical consequences all matter.

PATHFINDER 2

GRAIL reported that adding Galleri to recommended screening increased the number of cancers identified through screening. It also reported that more than half of newly detected cancers were Stage I or II and that the predicted cancer signal origin was accurate more than 90% of the time.

These company-reported findings formed part of the FDA submission. Regulatory review and peer-reviewed publication remain important for judging how the evidence applies to routine practice.

Is the Galleri Test FDA-Approved?

Not as of the October 27, 2026 editorial cutoff.

Galleri has been offered through GRAIL's CLIA-certified laboratory and received FDA Breakthrough Device designation in 2018. Breakthrough designation can facilitate communication and review, but it is not approval.

GRAIL submitted a premarket approval application on January 29, 2026. On September 23, an FDA advisory committee voted:

• 7–2, with one abstention, that Galleri's benefits outweigh its risks
• 10–0 that Galleri is safe
• 6–4 that Galleri is effective

The favorable vote is significant but not binding. The FDA considers advisory recommendations when making its final decision and can reach a different conclusion or impose conditions.

Does Medicare Cover Galleri?

Galleri did not have broad national Medicare coverage at the editorial cutoff. Coverage can vary through specific employer, commercial, or Medicare Advantage arrangements, so an individual should check directly with their plan.

FDA approval and reimbursement are separate. An approval decision would address the product's regulatory status; it would not by itself guarantee a national Medicare payment policy, broad commercial coverage, or a specific reimbursement amount.

This distinction is central to the business model. Galleri's out-of-pocket price can limit access, while broader coverage could expand testing volume. The timing and terms of any future coverage remain uncertain.

How Does GRAIL Make Money?

GRAIL reports screening revenue, primarily from Galleri, and a smaller amount of development-services revenue.

In Q2 2026, screening revenue was $42.6 million, while development-services revenue was approximately $2.0 million. Galleri therefore accounted for most of the $44.7 million total.

The long-term economics depend on more than the number of tests sold. Price, coverage, collection rates, laboratory cost, sales expense, clinical studies, regulatory cost, and follow-up requirements all influence profitability.

GRAL Stock Financial Overview

For the quarter ended June 30, 2026:

Adjusted gross profit and adjusted EBITDA are non-GAAP measures. The reported gross loss includes amortization of intangible assets, while the adjusted measure excludes specified items. Readers should use the reconciliation in GRAIL's release rather than treating adjusted figures as interchangeable with GAAP profit.

At June 30, GRAIL held $55.6 million in cash and cash equivalents plus $806.0 million in short-term marketable securities, totaling $861.6 million. The company completed a $110 million common-stock financing with Samsung entities in June 2026. The transaction added capital and potential international collaboration while increasing outstanding shares.

GRAL Stock Valuation

At the October 26 cutoff:

The approximate price-to-sales ratio divides the $6.249 billion market capitalization by $165.26 million of trailing revenue. It is a simple snapshot that does not account for cash, liabilities, future dilution, or changes in revenue.

Because earnings are negative, valuation depends heavily on assumptions about approval, reimbursement, adoption, pricing, gross margin, operating spending, and future capital needs.

GRAIL's Competitive Landscape

The cancer-detection market includes companies using methylation, mutation, protein, imaging, and other approaches. Direct comparison is difficult because products may target different cancers, patient groups, or clinical uses.

Guardant Health's Shield focuses on colorectal-cancer screening, while Exact Sciences markets established colorectal screening and has developed a multi-cancer blood test. Foundation Medicine primarily serves genomic profiling for patients with diagnosed cancer rather than screening asymptomatic populations.

GRAIL's distinguishing features include the breadth of its Galleri signal detection, its cancer signal origin prediction, and its large interventional-study program. These are potential advantages, not proof of superior outcomes or permanent market leadership.

GRAL Stock: Growth Drivers and Risks

Potential growth drivers

• A favorable final FDA decision and workable approval conditions
• Continued Galleri test-volume and revenue growth
• Broader employer, health-system, and payer access
• Evidence that supports clinical utility and efficient follow-up
• Improved unit economics and operating leverage
• Responsible expansion into additional markets and precision-oncology uses

Main risks

• Regulatory risk: The advisory vote does not guarantee FDA approval.
• Clinical risk: The NHS-Galleri combined Stage III and IV endpoint was not statistically significant.
• Reimbursement risk: Broad coverage and payment terms remain uncertain.
• Product concentration: Galleri generates most revenue.
• Loss and financing risk: GRAIL remains unprofitable and may need more capital.
• Dilution risk: Equity financing increases the number of shares outstanding.
• Competition risk: Other diagnostic approaches may gain evidence, approval, coverage, or adoption.
• Adoption risk: Clinicians and patients must understand both the potential benefit and follow-up burden.
• Valuation risk: A high price-to-sales ratio leaves the stock sensitive to changing expectations.

How to Research or Access GRAL Markets

Use GRAIL's official earnings releases, clinical publications, FDA materials, and SEC filings to assess the business. Pay attention to reporting dates and distinguish a regulatory recommendation from approval and approval from reimbursement.

Eligible users can also review the GRALUSDT perpetual market on Bybit. A perpetual is a derivative that provides price exposure; it is not ownership of GRAIL shares and does not provide voting, dividend, or other shareholder rights. Funding, leverage, liquidation, basis, trading-hour, and jurisdictional risks should be assessed separately.

Frequently Asked Questions About GRAL Stock

What is GRAL stock?

GRAL is the Nasdaq ticker for GRAIL, Inc., a healthcare company developing blood-based cancer-screening and precision-oncology tests. Its main commercial product is Galleri.

What does the Galleri test do?

Galleri analyzes methylation patterns in cell-free DNA to look for cancer-associated signals and predict a likely signal origin. It is a screening test, not a diagnosis, and should be used alongside recommended screening.

Is Galleri FDA-approved?

Not at the October 27, 2026 editorial cutoff. An FDA advisory committee voted favorably in September, but the agency's final decision was still pending.

Who is GRAIL's CEO?

Josh Ofman, MD, MSHS, is GRAIL's chief executive officer.

Where is GRAIL headquartered?

GRAIL's latest official materials list Sunnyvale, California. Older materials may refer to Menlo Park.

Is GRAL profitable?

No. GRAIL reported a $110.2 million net loss for Q2 2026. Revenue and Galleri volume grew, but they did not cover the company's reported costs and operating expenses.

Does GRAL pay a dividend?

No indicated dividend was shown in the October 26 market snapshot. GRAIL is funding clinical, regulatory, and commercial development.

Does Medicare cover Galleri?

Galleri did not have broad national Medicare coverage at the editorial cutoff. Coverage may vary under specific plans or programs. FDA approval would not automatically create national Medicare coverage.

Why did GRAIL separate from Illumina?

U.S. and European regulators challenged Illumina's acquisition of GRAIL on competition grounds. Illumina separated GRAIL in June 2024, and GRAL began regular-way Nasdaq trading on June 25.

Was GRAL launched through a traditional IPO?

No. GRAL reached the public market through a spin-off and regulatory divestiture. It did not have a conventional offering price; its first regular-way session closed at $17.00.

Is a GRAL perpetual the same as buying GRAL stock?

No. A perpetual is a derivative linked to price movement. It is not a Nasdaq-listed share and does not confer ownership or shareholder rights.

Conclusion

GRAL stock provides concentrated exposure to GRAIL and the Galleri multi-cancer early detection platform. By Q2 2026, test volume and revenue were growing, and the September advisory vote marked important regulatory progress. The company nevertheless remained unprofitable, broad reimbursement was uncertain, and final FDA approval was still pending.

Understanding GRAL therefore requires more than tracking the share price. Readers should follow the exact clinical endpoints, final regulatory decision, coverage policies, test economics, losses, and future financing.

Sources and cutoffs: Market price, range, market capitalization, trailing revenue, net income, EPS, beta, and dividend data are from Yahoo Finance GRAL through October 26, 2026. Financial and test-volume figures are from GRAIL's Q2 2026 results. FDA submission and advisory-vote details are from GRAIL's September 23 regulatory update. Corporate filings are available through GRAIL's SEC filings page. Q3 2026 results were scheduled for November 4 and were not available at the October 27 editorial cutoff.

Medical and investment disclaimer: This article is for informational and educational purposes only. It is not medical, financial, investment, legal, or tax advice. Galleri results require consultation with a qualified healthcare professional. Investing in an individual stock can result in loss.